Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down – What’s Next?

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares gapped down before the market opened on Wednesday . The stock had previously closed at $53.52, but opened at $48.90. Zealand Pharma A/S shares last traded at $48.90, with a volume of 179 shares traded.

Wall Street Analyst Weigh In

ZLDPF has been the topic of several analyst reports. Cantor Fitzgerald reiterated a “neutral” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. BNP Paribas Exane cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. Finally, William Blair restated a “market perform” rating on shares of Zealand Pharma A/S in a research note on Friday, March 6th. Three research analysts have rated the stock with a Strong Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy”.

Zealand Pharma A/S Price Performance

The stock has a market cap of $3.50 billion, a price-to-earnings ratio of 3.63 and a beta of 0.87. The company has a 50-day moving average of $46.42 and a 200-day moving average of $62.50. The company has a debt-to-equity ratio of 0.02, a quick ratio of 23.57 and a current ratio of 23.57.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.37) by $0.50. The firm had revenue of $5.33 million for the quarter, compared to analysts’ expectations of $2.81 million. Zealand Pharma A/S had a return on equity of 41.50% and a net margin of 68.82%. As a group, equities research analysts predict that Zealand Pharma A/S will post 2.7 earnings per share for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.